Barclays PLC Raises Holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

Barclays PLC lifted its holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) by 9.9% during the fourth quarter, Holdings Channel reports. The fund owned 55,161 shares of the company’s stock after buying an additional 4,951 shares during the quarter. Barclays PLC’s holdings in Lexeo Therapeutics were worth $363,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Lexeo Therapeutics in the fourth quarter worth approximately $46,000. JPMorgan Chase & Co. grew its stake in Lexeo Therapeutics by 135.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 10,278 shares of the company’s stock worth $93,000 after purchasing an additional 5,915 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Lexeo Therapeutics during the fourth quarter worth $72,000. Wells Fargo & Company MN increased its stake in Lexeo Therapeutics by 49.9% in the fourth quarter. Wells Fargo & Company MN now owns 11,156 shares of the company’s stock valued at $73,000 after purchasing an additional 3,714 shares during the last quarter. Finally, Rhumbline Advisers increased its position in shares of Lexeo Therapeutics by 19.6% during the fourth quarter. Rhumbline Advisers now owns 25,197 shares of the company’s stock worth $166,000 after purchasing an additional 4,127 shares in the last quarter. 60.67% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

LXEO has been the topic of several recent analyst reports. Leerink Partners dropped their target price on Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a research report on Monday, March 24th. HC Wainwright reaffirmed a “buy” rating and set a $23.00 price target on shares of Lexeo Therapeutics in a research report on Tuesday, April 8th. Chardan Capital reduced their target price on shares of Lexeo Therapeutics from $25.00 to $22.00 and set a “buy” rating on the stock in a report on Tuesday, April 8th. Finally, Royal Bank of Canada dropped their target price on Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 25th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $22.20.

Lexeo Therapeutics Stock Performance

NASDAQ:LXEO opened at $2.69 on Friday. The company has a market cap of $89.30 million, a price-to-earnings ratio of -0.85 and a beta of 1.27. Lexeo Therapeutics, Inc. has a 52-week low of $1.45 and a 52-week high of $19.50. The firm’s 50-day moving average is $3.06 and its 200-day moving average is $5.17. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.95 and a current ratio of 5.95.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.09. Equities research analysts anticipate that Lexeo Therapeutics, Inc. will post -3.14 earnings per share for the current year.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.